Successful gene therapy requires targeting the vast majority of cancer cells

References

• Rosenberg SA, Aebersold P, Cornetta K, Kasid A, Morgan RA, Moen R, Karson EM, Lotze MT, Yang JC, Topalian SL, et al. Gene transfer into humans–immunotherapy of patients with advanced melanoma, using tumor-infiltrating lymphocytes modified by retroviral gene transduction. N Engl J Med. 1990;323:570–578. doi:10.1056/NEJM199008303230904.
   PubMed Web of Science ®Google Scholar
• Wu ZJ, Tang FR, Ma ZW, Peng XC, Xiang Y, Zhang Y, Kang J, Ji J, Liu XQ, Wang XW, et al. Oncolytic viruses for tumor precision imaging and radiotherapy. Hum Gene Ther. 2018;29:204–222. doi:10.1089/hum.2017.189.
   PubMed Web of Science ®Google Scholar
• Shi C, Parker AR, Hua L, Morrell CN, Lee SC, Bandaru V, Dumler JS, Wu TC, Eshleman JR. Anti-gene padlocks eliminate Escherichia coli based on their genotype. J Antimicrob Chemother. 2008;61:262–272. doi:10.1093/jac/dkm482.
   PubMed Web of Science ®Google Scholar
• Chen ZH, Yu YP, Zuo ZH, Nelson JB, Michalopoulos GK, Monga S, Liu S, Tseng G, Luo JH. Targeting genomic rearrangements in tumor cells through Cas9-mediated insertion of a suicide gene. Nat Biotechnol. 2017;35:543–550. doi:10.1038/nbt.3843.
   PubMed Web of Science ®Google Scholar
• Zhang J, Kale V, Chen M. Gene-directed enzyme prodrug therapy. Aaps J. 2015;17:102–110. doi:10.1208/s12248-014-9675-7.
   PubMed Web of Science ®Google Scholar
• Smith JK, Agbandje-McKenna M. Creating an arsenal of Adeno-associated virus (AAV) gene delivery stealth vehicles. PLoS Pathog. 2018;14:e1006929. doi:10.1371/journal.ppat.1006929.
   PubMed Web of Science ®Google Scholar
• Jiang Q, Zhao S, Liu J, Song L, Wang ZG, Ding B. Rationally designed DNA-based nanocarriers. Adv Drug Deliv Rev. 2019. doi:10.1016/j.addr.2019.02.003.
   PubMed Web of Science ®Google Scholar
• Zhuo H, Zheng B, Liu J, Huang Y, Wang H, Zheng D, Mao N, Meng J, Zhou S, Zhong L, et al. Efficient targeted tumor imaging and secreted endostatin gene delivery by anti-CD105 immunoliposomes. J Exp Clin Cancer Res. 2018;37:42. doi:10.1186/s13046-018-0712-8.
   PubMed Web of Science ®Google Scholar
• no authors listed. Voretigene neparvovec-rzyl (Luxturna) for inherited retinal dystrophy. Med Lett Drugs Ther. 2018;60:53–55.
   PubMed Web of Science ®Google Scholar
• Pol J, Kroemer G, Galluzzi L. First oncolytic virus approved for melanoma immunotherapy. Oncoimmunology. 2016;5:e1115641. doi:10.1080/2162402X.2015.1115641.
   PubMed Web of Science ®Google Scholar
• Moolten FL. Tumor chemosensitivity conferred by inserted herpes thymidine kinase genes: paradigm for a prospective cancer control strategy. Cancer Res. 1986;46:5276–5281.
   PubMed Web of Science ®Google Scholar
• Mullen CA, Kilstrup M, Blaese RM. Transfer of the bacterial gene for cytosine deaminase to mammalian cells confers lethal sensitivity to 5-fluorocytosine: a negative selection system. Proc Natl Acad Sci U S A. 1992;89:33–37. doi:10.1073/pnas.89.1.33.
   PubMed Web of Science ®Google Scholar
• Freeman SM, Abboud CN, Whartenby KA, Packman CH, Koeplin DS, Moolten FL, Abraham GN. The “bystander effect”: tumor regression when a fraction of the tumor mass is genetically modified. Cancer Res. 1993;53:5274–5283.
   PubMed Web of Science ®Google Scholar
• Dilber MS, Abedi MR, Christensson B, Bjorkstrand B, Kidder GM, Naus CC, Gahrton G, Smith CI. Gap junctions promote the bystander effect of herpes simplex virus thymidine kinase in vivo. Cancer Res. 1997;57:1523–1528.
   PubMed Web of Science ®Google Scholar
• Dong Y, Wen P, Manome Y, Parr M, Hirshowitz A, Chen L, Hirschowitz EA, Crystal R, Weichselbaum R, Kufe DW, et al. In vivo replication-deficient adenovirus vector-mediated transduction of the cytosine deaminase gene sensitizes glioma cells to 5-fluorocytosine. Hum Gene Ther. 1996;7:713–720. doi:10.1089/hum.1996.7.6-713.
   PubMed Web of Science ®Google Scholar
• Trinh QT, Austin EA, Murray DM, Knick VC, Huber BE. Enzyme/prodrug gene therapy: comparison of cytosine deaminase/5-fluorocytosine versus thymidine kinase/ganciclovir enzyme/prodrug systems in a human colorectal carcinoma cell line. Cancer Res. 1995;55:4808–4812.
   PubMed Web of Science ®Google Scholar
• Huber BE, Austin EA, Richards CA, Davis ST, Good SS. Metabolism of 5-fluorocytosine to 5-fluorouracil in human colorectal tumor cells transduced with the cytosine deaminase gene: significant antitumor effects when only a small percentage of tumor cells express cytosine deaminase. Proc Natl Acad Sci U S A. 1994;91:8302–8306. doi:10.1073/pnas.91.17.8302.
   PubMed Web of Science ®Google Scholar
• Nadal JC, van Groeningen CJ, Pinedo HM, Peters GJ. Schedule-dependency of in vivo modulation of 5-fluorouracil by leucovorin and uridine in murine colon carcinoma. Invest New Drugs. 1989;7:163–172. doi:10.1007/BF00170853.
   PubMed Web of Science ®Google Scholar
• Cloughesy TF, Landolfi J, Hogan DJ, Bloomfield S, Carter B, Chen CC, Elder JB, Kalkanis SN, Kesari S, Lai A, et al. Phase 1 trial of vocimagene amiretrorepvec and 5-fluorocytosine for recurrent high-grade glioma. Sci Transl Med. 2016;8:341ra75. doi:10.1126/scitranslmed.aad9784.
   PubMed Web of Science ®Google Scholar
• Freytag SO, Stricker H, Lu M, Elshaikh M, Aref I, Pradhan D, Levin K, Kim JH, Peabody J, Siddiqui F, et al. Prospective randomized phase 2 trial of intensity modulated radiation therapy with or without oncolytic adenovirus-mediated cytotoxic gene therapy in intermediate-risk prostate cancer. Int J Radiat Oncol Biol Phys. 2014;89:268–276. doi:10.1016/j.ijrobp.2014.02.034.
   PubMed Web of Science ®Google Scholar
• Meliani A, Boisgerault F, Hardet R, Marmier S, Collaud F, Ronzitti G, Leborgne C, Costa Verdera H, Simon Sola M, Charles S, et al. Antigen-selective modulation of AAV immunogenicity with tolerogenic rapamycin nanoparticles enables successful vector re-administration. Nat Commun. 2018;9:4098. doi:10.1038/s41467-018-06621-3.
   PubMed Web of Science ®Google Scholar
• Wright CM, Wright RC, Eshleman JR, Ostermeier M. A protein therapeutic modality founded on molecular regulation. Proc Natl Acad Sci U S A. 2011;108:16206–16211. doi:10.1073/pnas.1102803108.
   PubMed Web of Science ®Google Scholar
• Wright RC, Khakhar A, Eshleman JR, Ostermeier M. Advancements in the development of HIF-1alpha-activated protein switches for use in enzyme prodrug therapy. PloS One. 2014;9:e114032. doi:10.1371/journal.pone.0114032.
   PubMed Web of Science ®Google Scholar
• Boyd D, Florent G, Kim P, Brattain M. Determination of the levels of urokinase and its receptor in human colon carcinoma cell lines. Cancer Res. 1988;48:3112–3116.
   PubMed Web of Science ®Google Scholar
• Korkegian A, Black ME, Baker D, Stoddard BL. Computational thermostabilization of an enzyme. Science. 2005;308:857–860. doi:10.1126/science.1107387.
   PubMed Web of Science ®Google Scholar